Share This Author
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation and had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash and an increased serum creatinine level than the placebo group.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.
In this trial, prophylactic ICD implantation in patients with symptomatic systolic heart failure not caused by coronary artery disease was not associated with a significantly lower long-term rate of death from any cause than was usual clinical care.
Association of national initiatives to improve cardiac arrest management with rates of bystander intervention and patient survival after out-of-hospital cardiac arrest.
An increase in survival following out-of-hospital cardiac arrest was significantly associated with a concomitant increase in bystander CPR in Denmark between 2001 and 2010, and the number of survivors per 100,000 persons increased significantly.
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding.
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
CHA2DS2-VASc performed better than CHADS2 in predicting patients at high risk, and those categorised as low risk by CHA2 DS2- VASc were truly at low risk for thromboembolism.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study…
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure.
Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’
This study is the first to establish reference and normal values for PWV, combining a sizeable European population after standardizing results for different methods of PWV measurement.
Increased mortality after dronedarone therapy for severe heart failure.
In patients with severe heart failure and left ventricular systolic dysfunction, treatment with dronedarone was associated with increased early mortality related to the worsening of heart failure.